Apr 27, 2016 · We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and ...
Sobh, M ; Michallet, M ; Gahrton, G et al. / Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A ...
Allogeneic hematopoietic cell transplantation for multiple myeloma ...
freidok.uni-freiburg.de › data
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies ...
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies ...
Aug 18, 2023 · Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative in some, while toxic in many others.
Gahrton, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic ...
Mar 6, 2023 · In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers.
We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with ...
This. Handbook addresses the most recent developments and innovations in HCT and cellular therapy, presented by more than 200 authors, known as experts and well ...
Comparison of Outcomes of Allogeneic Hematopoietic Cell ...
www.astctjournal.org › article › fulltext
Durable clinical remission can be achieved in 11% to 25% of patients with multiple myeloma with the use of allo-HCT without any significant difference in the ...
Missing: Malignancies | Show results with:Malignancies